Depression treatment market is segmented on the basis of antidepressants drugs, devices and therapies. Antidepressants are the largest market segment. Antidepressants are the most popular treatment methods. Every year more than five billion prescriptions are written globally. Antidepressants segment consists of big pharmaceuticals companies like Eli Lily, Pfizer, GlaxoSmithKline and Forest Laboratories. All these companies are branded drug manufacturers. Some of the popular drugs produced by these companies are Cymbalta (Eli Lily) and Effexor and Pristiq (Pfizer). The devices market is the fastest growing market segment.
1. Pfizer
2. GlaxoSmithKline
3. Forest Laboratories
4. Abbot Laboratories
5. Eli Lilly and Company
6. Merck Sharp &Dohme
7. Sanofi
8. Teva Pharmaceuticals Industries
9. Mayo Clinic
10. Sun Pharmaceuticals
11. Brainsway
12. Fisher Wallace
13. MagVentures
14. Lundbeck
15. BoehringerIngelheim GmbH
16. Roche Holding AG
2. GlaxoSmithKline
3. Forest Laboratories
4. Abbot Laboratories
5. Eli Lilly and Company
6. Merck Sharp &Dohme
7. Sanofi
8. Teva Pharmaceuticals Industries
9. Mayo Clinic
10. Sun Pharmaceuticals
11. Brainsway
12. Fisher Wallace
13. MagVentures
14. Lundbeck
15. BoehringerIngelheim GmbH
16. Roche Holding AG
This Occams Research Report covers
1. Historical data
2. Revenue forecasts, growth rates and CAGR upto 2021
3. Industry Analysis
4. Competitive Analysis
5. Key geographic growth data
6. Deep profiles top competitive companies
1. Historical data
2. Revenue forecasts, growth rates and CAGR upto 2021
3. Industry Analysis
4. Competitive Analysis
5. Key geographic growth data
6. Deep profiles top competitive companies
Browse For Full Report: http://www.acutemarketreports.com/report/global-depression-therapy-treatment-market
Chap 1. Executive Summary
1.1. Depression therapy, device and drugs market
1.2. Methodology For Market Estimation
1.1. Depression therapy, device and drugs market
1.2. Methodology For Market Estimation
Chap 2. Market Overview –Depression Is A Major Concern Worldwide
2.1. Introduction
2.2. Depression is most common in 40-60 years of age group
2.3. Types of Depressions
2.3.1. Seasonal Affective Disorder (SAD)
2.3.2. Uni-polar or Major Depression
2.3.3. Dysthymia or Dysthymia Disorder
2.3.4. Postpartum Depression
2.3.5. Atypical Depression
2.3.5.1. Psychotic Depression
2.3.5.2. Bipolar Disorder
2.4. Value Chain Analysis
2.4.1. For Drugs
2.4.1.1. Manufacturers
2.4.1.2. Distributors
2.4.1.3. Retailers
2.4.1.4. End-Users
2.4.2. For Devices
2.4.2.1. Manufacturers
2.4.2.2. Distributors
2.4.2.3. End-Users
2.5. Drivers
2.5.1. Growing acceptance of Depression in the developing nations
2.5.2. Increase in sales of antidepressants due to unhealthy life styles
2.6. Restraints
2.6.1. High price of Psycho therapy is a major restraint
2.6.2. Patents expiry is a major issue
2.6.3. Regulatory Compliance is important for the market to grow
2.7. Challenges
2.7.1. Generic Vs Branded – leads to price reduction
2.8. Opportunities
2.8.1. Significant Unmet Clinical needs has tremendous market potential
2.8.2. Decline in drug market offset bygrowing demand for personal therapies & devices
2.9. Key Findings
2.9.1. Negative Growth Rate in Antidepressants market
2.9.2. Rising acceptance for depression treatment in Asia Pacific
2.9.3. Market is shifting from branded to generic drugs
2.10. Strategic Recommendations
2.10.1. Market needs new anti depressant drugs
2.1. Introduction
2.2. Depression is most common in 40-60 years of age group
2.3. Types of Depressions
2.3.1. Seasonal Affective Disorder (SAD)
2.3.2. Uni-polar or Major Depression
2.3.3. Dysthymia or Dysthymia Disorder
2.3.4. Postpartum Depression
2.3.5. Atypical Depression
2.3.5.1. Psychotic Depression
2.3.5.2. Bipolar Disorder
2.4. Value Chain Analysis
2.4.1. For Drugs
2.4.1.1. Manufacturers
2.4.1.2. Distributors
2.4.1.3. Retailers
2.4.1.4. End-Users
2.4.2. For Devices
2.4.2.1. Manufacturers
2.4.2.2. Distributors
2.4.2.3. End-Users
2.5. Drivers
2.5.1. Growing acceptance of Depression in the developing nations
2.5.2. Increase in sales of antidepressants due to unhealthy life styles
2.6. Restraints
2.6.1. High price of Psycho therapy is a major restraint
2.6.2. Patents expiry is a major issue
2.6.3. Regulatory Compliance is important for the market to grow
2.7. Challenges
2.7.1. Generic Vs Branded – leads to price reduction
2.8. Opportunities
2.8.1. Significant Unmet Clinical needs has tremendous market potential
2.8.2. Decline in drug market offset bygrowing demand for personal therapies & devices
2.9. Key Findings
2.9.1. Negative Growth Rate in Antidepressants market
2.9.2. Rising acceptance for depression treatment in Asia Pacific
2.9.3. Market is shifting from branded to generic drugs
2.10. Strategic Recommendations
2.10.1. Market needs new anti depressant drugs
Chap 3. Market Segmentation
3.1. Antidepressants
3.2. Consumption of Antidepressants
3.2.1. Generic Drugs are preferred OVER Branded Antidepressants due to lower cost
3.3. Selective serotonin reuptake inhibitors (SSRIs)
3.3.1. Prozac (Fluoxetine)
3.3.2. Paroxetine (Paxil)
3.3.3. SERTRALINE (Zoloft)
3.1. Antidepressants
3.2. Consumption of Antidepressants
3.2.1. Generic Drugs are preferred OVER Branded Antidepressants due to lower cost
3.3. Selective serotonin reuptake inhibitors (SSRIs)
3.3.1. Prozac (Fluoxetine)
3.3.2. Paroxetine (Paxil)
3.3.3. SERTRALINE (Zoloft)
Browse For Same Category: http://www.acutemarketreports.com/category/pharmaceutical-market
3.3.4. Escitalopram oxalate (Lexapro)
3.3.5. Citalopram (Celexa)
3.3.6. Serotonin and norepinephrine reuptake inhibitors (SNRIs).
3.3.7. Duloxetine (Cymbalta)
3.3.8. Effexor
3.3.9. Norepinephrine and dopamine reuptake inhibitors (NDRIs)
3.4. Atypical antidepressants
3.4.1. Trazodone
3.4.2. Tricyclic antidepressants (TCA)
3.4.3. Tofranil (Imipramine)
3.4.4. Monoamine oxidase inhibitors (MAOIs)
3.4.4.1. Tranylcypromine (Parnate)
3.4.5. Phenelzine (Nardil)
3.4.6. Other medications
3.5. Therapies
3.5.1. Cognitive Behavior Therapy (CBT)
3.5.2. Electroconvulsive Therapy (ECT)
3.5.3. Rational emotive behavior therapy (REBT)
3.5.4. Device enabled therapies
3.5.4.1. Transcranial Magnetic Stimulation (TMS) therapy
3.5.4.2. Deep Brain Stimulation
3.5.4.3. Vagus Nerve Stimulator
3.5.4.4. Virtual Reality (VR)
3.5.4.5. Smart phone applications
3.5.5. Other Therapies
3.5.5.1. Ketamine therapy
3.5.6. Special Conditions
3.5.6.1. Antidepressants discontinuation syndrome (ADS)
3.5.6.2. Treatment-resistant depression
3.5.6.3. Rehabilitation centre for depression
3.5.6.4. Rehabilitation programs through VR technology
3.3.4. Escitalopram oxalate (Lexapro)
3.3.5. Citalopram (Celexa)
3.3.6. Serotonin and norepinephrine reuptake inhibitors (SNRIs).
3.3.7. Duloxetine (Cymbalta)
3.3.8. Effexor
3.3.9. Norepinephrine and dopamine reuptake inhibitors (NDRIs)
3.4. Atypical antidepressants
3.4.1. Trazodone
3.4.2. Tricyclic antidepressants (TCA)
3.4.3. Tofranil (Imipramine)
3.4.4. Monoamine oxidase inhibitors (MAOIs)
3.4.4.1. Tranylcypromine (Parnate)
3.4.5. Phenelzine (Nardil)
3.4.6. Other medications
3.5. Therapies
3.5.1. Cognitive Behavior Therapy (CBT)
3.5.2. Electroconvulsive Therapy (ECT)
3.5.3. Rational emotive behavior therapy (REBT)
3.5.4. Device enabled therapies
3.5.4.1. Transcranial Magnetic Stimulation (TMS) therapy
3.5.4.2. Deep Brain Stimulation
3.5.4.3. Vagus Nerve Stimulator
3.5.4.4. Virtual Reality (VR)
3.5.4.5. Smart phone applications
3.5.5. Other Therapies
3.5.5.1. Ketamine therapy
3.5.6. Special Conditions
3.5.6.1. Antidepressants discontinuation syndrome (ADS)
3.5.6.2. Treatment-resistant depression
3.5.6.3. Rehabilitation centre for depression
3.5.6.4. Rehabilitation programs through VR technology
Chap 4. Depression Prevalence by Gender
4.1. Depression in Men
4.2. Depression in Women
4.2.1. Depression in Elderly is a common phenomenon
4.1. Depression in Men
4.2. Depression in Women
4.2.1. Depression in Elderly is a common phenomenon
About – Acute Market Reports:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Name: Chris Paul
ACUTE MARKET REPORTS
Designation: Global Sales Manager
Toll Free(US/CANADA): +1-855-455-8662
Email: sales@acutemarketreports.com
Website: http://www.acutemarketreports.com
No comments:
Post a Comment